Full Press Release Details
Keros Therapeutics to Present at Upcoming Healthcare Conferences
November 22, 2022 at 8 00 a.m. EST
LEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in fireside chat presentations at the Piper Sandler 34th Annual Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference.
Fireside Chat Presentation Details
Piper Sandler 34th Annual Healthcare Conference
Date and Time Tuesday, November 29 at 10 00 a.m. Eastern time
Link A live audio webcast will be available at https event.webcasts.com starthere.jsp ei 1583421 tp_key 815a14dcdc
5th Annual Evercore ISI HealthCONx Conference
Date and Time Thursday, December 1 at 8 50 a.m. Eastern time
Link A live audio webcast will be available at https wsw.com webcast evercore29 kros 2399130
For each fireside chat, an archived replay will be available in the Investors section of the Keros website at https ir.kerostx.com for 90 days following the conclusion of the event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Keros is a leader in understanding the role of the TGF- family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of a number of tissues, including blood vessels and heart tissue. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Keros' third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders associated with cardiac hypertrophy.